European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults
Por:
Méroc E, Fröberg J, Almasi T, Winje BA, Orrico-Sánchez A, Steens A, McDonald SA, Bollaerts K and Knol MJ
Publicada:
13 abr 2021
Ahead of Print:
13 abr 2021
Categoría:
Infectious diseases
Resumen:
BackgroundTo guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.MethodsWe conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019.ResultsMorbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC.ConclusionThis study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.
Filiaciones:
Méroc E:
P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001, Leuven, Belgium.
Fröberg J:
Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Laboratory of Medical Immunology, Section Paediatric Infectious Diseases, Geert Grooteplein 21, 6525 EZ, Nijmegen, the Netherlands
Almasi T:
Syreon Research Institute, Mexikoi str. 65/A, Budapest, 1142, Hungary
Winje BA:
Department of Infection Control and Vaccine, Norwegian Institute of Public Health, PO Box 222, Skøyen, 0213, Oslo, Norway
:
Vaccines Research Unit, FISABIO (the Valencia Foundation for the Promotion of Health and Biomedical Research), Av. Catalunya, 21, 46020, Valencia, Spain
Steens A:
Department of Infection Control and Vaccine, Norwegian Institute of Public Health, PO Box 222, Skøyen, 0213, Oslo, Norway
McDonald SA:
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, the Netherlands
Bollaerts K:
P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001, Leuven, Belgium
Knol MJ:
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, the Netherlands
Green Published, gold
|